1 / 6

Hazard Ratio 0.62 (0.41-0.94) P = .024

Larynx and Hypopharynx Overall Survival. Hazard Ratio 0.62 (0.41-0.94) P = .024. 166 Patients. Larynx and Hypopharynx OS and PFS. OS “Operable” Hypopharynx and Larynx Patients. Hazard Ratio 0.67 (0.41-1.11) P = 0.12. 123 Patients. LFS in the Operable Patient Population.

kalkin
Download Presentation

Hazard Ratio 0.62 (0.41-0.94) P = .024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Larynx and Hypopharynx Overall Survival Hazard Ratio 0.62 (0.41-0.94) P = .024 166 Patients

  2. Larynx and Hypopharynx OS and PFS

  3. OS “Operable” Hypopharynx and Larynx Patients Hazard Ratio 0.67 (0.41-1.11) P = 0.12 123 Patients

  4. LFS in the Operable Patient Population Hazard Ratio 0.59 (0.37-0.95) P = .03

  5. TAX 324 – Larynx and HypopharynxConclusions • Sequential Therapy with TPF Significantly Improves Survival in Advanced Larynx and Hypopharynx Cancer • TPF Reduces Mortality by 38% Compared to PF, p = .02 • Sequential Therapy with TPF Significantly Improves PFS in Advanced Larynx and Hypopharynx Cancer • TPF Improves PFS by 34% Compared to PF, p = .03 • TPF Reduces Surgery by 50%, p = .026 • TPF Reduces Primary Site Surgery

  6. TAX 324 – Larynx and HypopharynxRational Speculation • Sequential Therapy With TPF Significantly Improves LFS in Operable Larynx and Hypopharynx Cancer Compared To PF, p = .03 • Since TPF Is Significantly Better Than PF, We Could Reasonably Expect TPF To Be Significantly Better Than Bolus Cisplatin-Based CRT • PF Is Equivalent To Bolus Cisplatin-Based CRT for LFS and Survival* • There Is A Significant Survival and LFS Advantage To TPF Compared to PF *Taylor, 1996, Forastiere, 2006; Lefebvre, 2007

More Related